Leerink Partners Maintains Outperform on Cytokinetics, Lowers Price Target to $100
Benzinga Newsdesk 3 hours ago
Analyst RatingsNewsPrice Target
Leerink Partners analyst Roanna Ruiz maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and lowers the price target from $103 to $100.
Leerink Partners analyst Roanna Ruiz maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and lowers the price target from $103 to $100.